Relative contribution of contact and complement activation to inflammatory reactions in arthritic joints.

Although both the complement and contact system are thought to contribute to the inflammatory reaction in arthritic joints, only activation of complement has so far been well established, whereas contact activation and its contribution to arthritis has not been systematically explored. Complement and contact activation were assessed in 71 patients with inflammatory arthropathies and 11 with osteoarthritis using sensitive assays for C3a, and C1-inhibitor (C1INH)-kallikrein and C1INH-factor XIIa complexes respectively. Increased plasma concentrations of kallikrein-and factor XIIa-C1INH complexes were found in two and seven of the 71 patients with inflammatory arthropathies, respectively, and in none of the patients with osteoarthritis. Increased synovial fluid concentrations of kallikrein and factor XIIa complexes occurred in 13 and 15 patients with inflammatory joint diseases respectively, and in two patients with osteoarthritis. Contact system parameters did not correlate with clinical symptoms, local activity, or neutrophil activation. In contrast, synovial fluid concentrations of C3a and C1INH-C1 complexes were increased in all patients and in 20 patients with inflammatory arthropathies respectively, and were higher in patients with a higher local activity score. Synovial fluid C3a correlated with parameters of neutrophil activation such as lactoferrin. Increased plasma concentrations of C3a and C1INH-C1 complexes occurred in 13 and 11 patients with inflammatory joint diseases, and in one and two patients with osteoarthritis respectively. Plasma concentrations of C3a correlated with the number of painful joints. Thus contact activation occurs only sporadically in patients with arthritis and contributes little if anything to the local inflammatory reaction and neutrophil activation. These latter events are significantly related to the extent of complement activation.

[1]  F. Arnett.  Revised criteria for the classification of rheumatoid arthritis. , 1990, Orthopedic nursing.

[2]  C. Hack,et al.  Proteolytic inactivation of plasma C1- inhibitor in sepsis. , 1989, The Journal of clinical investigation.

[3]  C. Hack,et al.  Quantification of plasma factor XIIa-Cl(-)-inhibitor and kallikrein-Cl(-)-inhibitor complexes in sepsis. , 1988, Blood.

[4]  L. Thijs,et al.  A modified competitive inhibition radioimmunoassay for the detection of C3a. Use of 125I-C3 instead of 125I-C3a. , 1988, Journal of immunological methods.

[5]  K. A. Brown.  The polymorphonuclear cell in rheumatoid arthritis. , 1988, British journal of rheumatology.

[6]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[7]  M. Doherty,et al.  Relation between synovial fluid C3 degradation products and local joint inflammation in rheumatoid arthritis, osteoarthritis, and crystal associated arthropathy. , 1988, Annals of the rheumatic diseases.

[8]  T. Mollnes,et al.  Complement activation in synovial fluid and tissue from patients with juvenile rheumatoid arthritis. , 1986, Arthritis and rheumatism.

[9]  S. Ruddy,et al.  Elevated C3 anaphylatoxin levels in synovial fluids from patients with rheumatoid arthritis. , 1985, Arthritis and rheumatism.

[10]  P. Lachmann,et al.  Simultaneous turnover of normal and dysfunctional C1 inhibitor as a probe of in vivo activation of C1 and contact activatable proteases. , 1985, Clinical and experimental immunology.

[11]  J. T. ten Cate,et al.  Activation and inhibition of Hageman factor-dependent pathways and the complement system in uncomplicated bacteremia or bacterial shock. , 1985, Journal of Infectious Diseases.

[12]  R. Colman,et al.  The regulation of human factor XIIa by plasma proteinase inhibitors. , 1985, The Journal of biological chemistry.

[13]  R. Colman,et al.  Effect of cleavage of the heavy chain of human plasma kallikrein on its functional properties. , 1985, Blood.

[14]  N. Mehra,et al.  HLA B27 related 'unclassifiable' seronegative spondyloarthropathies. , 1983, Annals of the rheumatic diseases.

[15]  T. Ingemann-Hansen,et al.  Complement C3c and C3d in plasma and synovial fluid in rheumatoid arthritis. , 1983, Acta pathologica, microbiologica, et immunologica Scandinavica. Section C, Immunology.

[16]  R. Inman,et al.  C1 inactivator-C1s complexes in inflammatory joint disease. , 1983, Clinical and experimental immunology.

[17]  P. Dieppe,et al.  Activation of the alternative pathway of complement by monosodium urate monohydrate crystals and other inflammatory particles. , 1983, Annals of the rheumatic diseases.

[18]  G. Weissmann.  Activation of neutrophils and the lesions of rheumatoid arthritis. , 1982, The Journal of laboratory and clinical medicine.

[19]  R. Colman,et al.  Purified human plasma kallikrein aggregates human blood neutrophils. , 1982, The Journal of clinical investigation.

[20]  T. Out,et al.  A C1-inhibitor-complex assay (INCA): a method to detect C1 activation in vitro and in vivo. , 1981, Journal of immunology.

[21]  J. Griffin,et al.  Urate crystal--dependent cleavage of Hageman factor in human plasma and synovial fluid. , 1980, The Journal of laboratory and clinical medicine.

[22]  N. Hadler,et al.  Lysosomal enzymes in inflammatory synovial effusions. , 1979, Journal of immunology.

[23]  P. Hasselbacher,et al.  C3 activation by monosodium urate monohydrate and other crystalline material. , 1979, Arthritis and rheumatism.

[24]  Robert B Sim,et al.  Interaction of 125I‐labelled complement subcomponents C r and C s with protease inhibitors in plasma , 1979, FEBS letters.

[25]  R. Zubler,et al.  Circulating complement breakdown products in patients with rheumatoid arthritis. Correlation between plasma C3d, circulating immune complexes, and clinical activity. , 1977, The Journal of clinical investigation.

[26]  D. Mccarty,et al.  Preliminary criteria for the classification of the acute arthritis of primary gout. , 1977, Arthritis and rheumatism.

[27]  P. Miescher,et al.  Correlation between levels of breakdown products of C3, C4, and properdin factor B in synovial fluids from patients with rheumatoid arthritis. , 1977, Arthritis and rheumatism.

[28]  V. Wright,et al.  New York clinical criteria for ankylosing spondylitis. A statistical evaluation. , 1973, Annals of the rheumatic diseases.

[29]  P. Ward,et al.  Complement as a mediator of inflammation in acute gouty arthritis. II. Biological activities generated from complement by the interaction of serum complement and sodium urate crystals. , 1973, The Journal of laboratory and clinical medicine.

[30]  K. Austen,et al.  A PREALBUMIN ACTIVATOR OF PREKALLIKREIN , 1972, The Journal of experimental medicine.

[31]  T. Astrup,et al.  Generation of kinin-like agents by chondroitin sulfate, heparin, chitin sulfate, and human articular cartilage: possible pathophysiologic implications. , 1970, The Journal of laboratory and clinical medicine.

[32]  K. Melmon,et al.  The presence of a kinin in inflammatory synovial effusion from arthritides of varying etiologies. , 1967, Arthritis and rheumatism.

[33]  R. Kellermeyer,et al.  THE INFLAMMATORY PROCESS IN ACUTE GOUTY ARTHRITIS. I. ACTIVATION OF HAGEMAN FACTOR BY SODIUM URATE CRYSTALS. , 1965, The Journal of laboratory and clinical medicine.

[34]  W. Vogt.  Anaphylatoxins: possible roles in disease. , 1986, Complement.

[35]  T. Hugli,et al.  Radioimmunoassay for anaphylatoxins: a sensitive method for determining complement activation products in biological fluids. , 1984, Analytical biochemistry.

[36]  F van der Graaf,et al.  Inactivation of kallikrein in human plasma. , 1983, The Journal of clinical investigation.

[37]  J. Griffin,et al.  The biochemistry and pathophysiology of the contact system of plasma. , 1982, Advances in immunology.

[38]  G. Hunder,et al.  Activation of complement components C3 and factor B in synovial fluids. , 1977, The Journal of laboratory and clinical medicine.

[39]  C. Keele,et al.  Plasma Kinin Formation in Rheumatoid Arthritis , 1970 .